LDS/Medical Tests/Nefazodone, Urine

Nefazodone, Urine

Nefazodone is a member of the class of drugs known as antidepressants. The use of tricyclic antidepressants (TCAs) is one of the primary ways to treat clinical depression. Depression and schizophrenia are the most common mental disorders that faces mankind at this time. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorders, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. Nefazodone is a member of the third generation of antidepressants.

All TCAs are well absorbed and reach peak serum concentrations within 2-12 hours. TCAs are lipophilic and have large volumes of distributions. Most TCAs are metabolized by the cytochrome P450 system and many of the metabolites are biologically active. Nefazodone is metabolized to M-chloro-phenylpiperazine hydroxynefazodone, which is also biologically active. The half-lives of these particular drugs are quite variable. The half-life of nefazodone is between 2-5 hours. Many of the therapeutic ranges for these drugs have not been established or there is non-consensus.

The effects associated with nefazodone abuse include headache, dry mouth, sexual dysfunction, hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.

Nefazodone is one of the most frequently encountered drugs of abuse due to the large majority of the population that is taking them, the frequency with which these drugs are prescribed, and their high potential for serious side effects.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from either Thin Layer Chromatography (TLC) or immunoassay (IA) type test indicates only the presence of TCAs and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, TLC, LC/MS or GC/MS.

Therapeutic levels: 0.30-0.50 mg/L
Toxic levels: variable
Fatality levels: variable

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection. whether it is a qualitative method such as TLC or IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy(LC/MS), Gas Chromatography/Mass Spectroscopy(GC/MS), Thin Layer Chromatography(TLC), or Immunoassay(IA). The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy). This particular method of analysis is used to detect TCAs such as nefazodone and its metabolite. Nefazodone can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step is required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Antidepressant DEA Drug Fact Sheet.
  • Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
  • Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.